Market capitalization | $7.99m |
Enterprise Value | $3.09m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 44.14 |
P/S ratio (TTM) P/S ratio | 114.14 |
P/B ratio (TTM) P/B ratio | 1.12 |
Revenue growth (TTM) Revenue growth | -83.60% |
Revenue (TTM) Revenue | $70.00k |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
1 Analyst has issued a forecast Organovo Holdings, Inc.:
1 Analyst has issued a forecast Organovo Holdings, Inc.:
Mar '24 |
+/-
%
|
||
Net Profit | -15 -15 |
15%
15%
|
|
Depreciation and Amortization | 0.28 0.28 |
3%
3%
|
|
Stock Compensation | 1.51 1.51 |
37%
37%
|
|
Operating Cash Flow | -15 -15 |
18%
18%
|
|
Investments | 0.04 0.04 |
90%
90%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -15 -15 |
15%
15%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Keith Murphy |
Employees | 20 |
Founded | 2012 |
Website | www.organovo.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.